Andika Yustiadenta Widya, Jannah Silka Roudhatul, Wildan Arief, Rahmi Fifin Luthfia, Prihatningtyas Riski, Mulyanto Joko
Department of Ophthalmology, Faculty of Medicine, Dr. Kariadi Hospital, Diponegoro University, Semarang, Indonesia.
Department of Ophthalmology, Glaucoma Division, Faculty of Medicine, Dr. Kariadi Hospital, Diponegoro University, Semarang, Indonesia.
J Adv Pharm Technol Res. 2023 Jul-Sep;14(3):258-262. doi: 10.4103/japtr.japtr_29_23. Epub 2023 Jul 28.
The purpose of this research is to determine how Mirtogenol affects intraocular pressure (IOP) and retinal ganglion cells (RGCs) of apoptosis index in Wistar glaucoma models, as well as the relationship between IOP and RGC apoptosis index. Twelve Wistar glaucoma models were divided into two groups for experimental research with a pretest-posttest and posttest-only. The treatment group got oral administration of Mirtogenol 12.3 mg twice a day for 2 weeks, whereas the control group received a placebo in the same way. Apoptotic index and IOP were evaluated both before and after the intervention. A parametric independent -test was used to determine the difference between groups, and a parametric paired -test was used to determine the difference within groups. The results showed that the RGC apoptosis index in treatment groups was considerably less when compared to control groups ( < 0.001). In the treatment group, the IOP is decreased compared to the control group (mean difference: -12.67 ± 3.79 vs. 0.69 ± 4.64, respectively, = 0.002). A significant and solid correlation was found between IOP and RGC apoptosis index ( = 0.884, < 0.001). Thus, Mirtogenol supplementation is expected to be used to prevent glaucoma progression.
本研究的目的是确定米托蒽醌对Wistar青光眼模型眼内压（IOP）和视网膜神经节细胞（RGCs）凋亡指数的影响，以及IOP与RGC凋亡指数之间的关系。将12只Wistar青光眼模型分为两组进行实验研究，采用前测-后测和仅后测的方法。治疗组每天口服12.3 mg米托蒽醌两次，持续2周，而对照组以相同方式接受安慰剂。在干预前后评估凋亡指数和IOP。采用参数独立检验确定组间差异，采用参数配对检验确定组内差异。结果显示，与对照组相比，治疗组的RGC凋亡指数显著降低（<0.001）。在治疗组中，与对照组相比IOP降低（平均差异：分别为-12.67±3.79和0.69±4.64，P=0.002）。发现IOP与RGC凋亡指数之间存在显著且密切的相关性（r=0.884，P<0.001）。因此，预计补充米托蒽醌可用于预防青光眼进展。
